Tactile Systems Technology

TCMD

Market cap $657M

The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tactile Systems Technology (TCMD) could produce exceptional returns because of its solid growth attributes.

Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 20-day moving average, which suggests a short-term bullish trend.

Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 50-day moving average, which suggests a short-term bullish trend.

The medical devices specialist posted its final set of figures for 2025. In the fourth quarter, it grew both revenue and profitability at impressive rates.

Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.

Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.4 per share a year ago.

MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 million Gross margin of 78% versus 75% in Q4 2024 Net income of $10.6 million versus $9.7 million in Q4 2024 Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 million Gross margin of 76%, compared to 74% in 2024 Operating cashflow of $42.8 million, compared to $40.7 million in 2024 Repaid full outstanding principal balance of $26.3 million under the Company's term loan Repurchased $26.5 million of stock at an average price of $12.36 per share Ended 2025 with $83.4 million in cash, compared to $94.4 million at the end of 2024 Recent Business Highlights Acquired LymphaTech, expanding our lymphedema solutions portfolio and strengthening our R&D capabilities with their digital 3D scanning technology for chronic swelling detection, measurement, and monitoring Announced the publication of two-month clinical data comparing Flexitouch Plus™ to usual care in the Journal of the Sciences and Specialties of the Head and Neck “In 2025, we executed with discipline against our core growth strategies, delivering double-digit revenue growth, expanding gross margin and adjusted EBITDA, and generating strong cash flow, while continuing to strategically invest in people and workflow-related processes to strengthen our business for scale,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.